News

Welcome to the BioMendics media center. BioMendics is advancing innovative science and developing new therapeutic options for people with rare dermatologic disorders. Learn more about our recent work below.

For specific inquiries, please Contact Us.

To learn more about the TAMES-02 clinical trial check out this BioMendics Press Release

The TAMES-02 study launch was also covered here:

BioSpace: https://www.biospace.com/press-releases/biomendics-launches-tames-02-clinical-trial-for-innovative-epidermolysis-bullosa-simplex-therapy

Dermatology Times: https://www.dermatologytimes.com/view/tames-02-trial-launches-for-eb-simplex-therapy

Yahoo Finance:https://finance.yahoo.com/news...

Associated Press: https://apnews.com/press-relea...

Boston Herald: https://markets.financialconte...

Wellness Insider: https://thewellnessinsider.asi...

MedPath: https://trial.medpath.com/news...

BioMendics Received Top Rare Dermatologic Disorders Medication Development 2025 from Life Sciences Review

Life Sciences Review: https://www.lifesciencesreview...